full

More documents

Recommendations

Info

Matsumura A, et al: ST2 for Transplant-related ComplicationsTurk J Hematol 2020;37:20-294. Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, Zhang Q, WongCH, Wang H, Chin A, Gomez A, Harris AC, Levine JE, Choi SW, Couriel D,Reddy P, Ferrara JL, Paczesny S. ST2 as a marker for risk of therapy-resistantgraft-versus-host disease and death. N Engl J Med 2013;369:529-539.5. Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R, MisekDE, Cooke KR, Kitko CL, Weyand A, Bickley D, Jones D, Whitfield J, Reddy P,Levine JE, Hanash SM, Ferrara JL. A biomarker panel for acute graft-versushostdisease. Blood 2009;113:273-278.6. Kennedy GA, Varelias A, Vuckovic S, Le Texier L, Gartlan KH, Zhang P, ThomasG, Anderson L, Boyle G, Cloonan N, Leach J, Sturgeon E, Avery J, Olver SD,Lor M, Misra AK, Hutchins C, Morton AJ, Durrant ST, SubramoniapillaiE, Butler JP, Curley CI, MacDonald KP, Tey SK, Hill GR. Addition ofinterleukin-6 inhibition with tocilizumab to standard graft-versus-hostdisease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2trial. Lancet Oncol 2014;15:1451-1459.7. Paczesny S, Braun TM, Levine JE, Hogan J, Crawford J, Coffing B, Olsen S,Choi SW, Wang H, Faca V, Pitteri S, Zhang Q, Chin A, Kitko C, Mineishi S,Yanik G, Peres E, Hanauer D, Wang Y, Reddy P, Hanash S, Ferrara JL. Elafinis a biomarker of graft-versus-host disease of the skin. Sci Transl Med2010;2:13ra12.8. Ferrara JL, Harris AC, Greenson JK, Braun TM, Holler E, Teshima T, LevineJE, Choi SW, Huber E, Landfried K, Akashi K, Vander Lugt M, Reddy P, ChinA, Zhang Q, Hanash S, Paczesny S. Regenerating islet-derived 3-alphais a biomarker of gastrointestinal graft-versus-host disease. Blood2011;118:6702-6708.9. Harris AC, Ferrara JL, Braun TM, Holler E, Teshima T, Levine JE, Choi SW,Landfried K, Akashi K, Vander Lugt M, Couriel DR, Reddy P, Paczesny S.Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood2012;119:2960-2963.10. Levine JE, Logan BR, Wu J, Alousi AM, Bolanos-Meade J, Ferrara JL, HoVT, Weisdorf DJ, Paczesny S. Acute graft-versus-host disease biomarkersmeasured during therapy can predict treatment outcomes: a Blood andMarrow Transplant Clinical Trials Network study. Blood 2012;119:3854-3860.11. Hansen JA, Hanash SM, Tabellini L, Baik C, Lawler RL, Grogan BM, Storer B,Chin A, Johnson M, Wong CH, Zhang Q, Martin PJ, McDonald GB. A novelsoluble form of Tim-3 associated with severe graft-versus-host disease. BiolBlood Marrow Transplant 2013;19:1323-1330.12. McDonald GB, Tabellini L, Storer BE, Lawler RL, Martin PJ, Hansen JA. Plasmabiomarkers of acute GVHD and nonrelapse mortality: predictive value ofmeasurements before GVHD onset and treatment. Blood 2015;126:113-120.13. Abu Zaid M, Wu J, Wu C, Logan BR, Yu J, Cutler C, Antin JH, Paczesny S,Choi SW. Plasma biomarkers of risk for death in a multicenter phase 3trial with uniform transplant characteristics post-allogeneic HCT. Blood2017;129:162-170.14. Yu J, Storer BE, Kushekhar K, Abu Zaid M, Zhang Q, Gafken PR, Ogata Y,Martin PJ, Flowers ME, Hansen JA, Arora M, Cutler C, Jagasia M, PidalaJ, Hamilton BK, Chen GL, Pusic I, Lee SJ, Paczesny S. Biomarker panel forchronic graft-versus-host disease. J Clin Oncol 2016;34:2583-2590.15. Rotz SJ, Dandoy CE, Davies SM. ST2 and endothelial injury as a link betweenGVHD and microangiopathy. N Engl J Med 2017;376:1189-1190.16. Akil A, Zhang Q, Mumaw CL, Raiker N, Yu J, Velez de Mendizabal N, HanelineLS, Robertson KA, Skiles J, Diaz-Ricart M, Carreras E, Renbarger J, HanashS, Bies RR, Paczesny S. Biomarkers for diagnosis and prognosis of sinusoidalobstruction syndrome after hematopoietic cell transplantation. Biol BloodMarrow Transplant 2015;21:1739-1745.17. Griesenauer B, Paczesny S. The ST2/IL-33 axis in immune cells duringinflammatory diseases. Front Immunol 2017;8:475.18. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK,Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-relatedprotein ST2 and induces T helper type 2-associated cytokines. Immunity2005;23:479-490.19. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back tothe future. Immunity 2013;39:1003-1018.20. Reichenbach DK, Schwarze V, Matta BM, Tkachev V, Lieberknecht E, LiuQ, Koehn BH, Pfeifer D, Taylor PA, Prinz G, Dierbach H, Stickel N, Beck Y,Warncke M, Junt T, Schmitt-Graeff A, Nakae S, Follo M, Wertheimer T,Schwab L, Devlin J, Watkins SC, Duyster J, Ferrara JL, Turnquist HR, ZeiserR, Blazar BR. The IL-33/ST2 axis augments effector T-cell responses duringacute GVHD. Blood 2015;125:3183-3192.21. Matta BM, Reichenbach DK, Zhang X, Mathews L, Koehn BH, Dwyer GK, LottJM, Uhl FM, Pfeifer D, Feser CJ, Smith MJ, Liu Q, Zeiser R, Blazar BR, TurnquistHR. Peri-alloHCT IL-33 administration expands recipient T-regulatory cellsthat protect mice against acute GVHD. Blood 2016;128:427-439.22. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, SlavinS, Pasquini M, Sandmaier BM, Barrett J, Blaise D, Lowski R, Horowitz M.Defining the intensity of conditioning regimens: working definitions. BiolBlood Marrow Transplant 2009;15:1628-1633.23. Marks R, Potthoff K, Hahn J, Ihorst G, Bertz H, Spyridonidis A, Holler E, FinkeJM. Reduced-toxicity conditioning with fludarabine, BCNU, and melphalanin allogeneic hematopoietic cell transplantation: particular activity againstadvanced hematologic malignancies. Blood 2008;112:415-425.24. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J,Thomas ED. 1994 Consensus Conference on Acute GVHD Grading. BoneMarrow Transplant 1995;15:825-828.25. Ruutu T, Barosi G, Benjamin RJ, Clark RE, George JN, Gratwohl A, Holler E,Iacobelli M, Kentouche K, Lammle B, Moake JL, Richardson P, Socie G, ZeiglerZ, Niederwieser D, Barbui T, European Group for B, Marrow T, EuropeanL. Diagnostic criteria for hematopoietic stem cell transplant-associatedmicroangiopathy: results of a consensus process by an InternationalWorking Group. Haematologica 2007;92:95-100.26. Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M, Ferrara J, SoifferR, Giralt S. Blood and marrow transplant clinical trials network toxicitycommittee consensus summary: thrombotic microangiopathy afterhematopoietic stem cell transplantation. Biol Blood Marrow Transplant2005;11:571-575.27. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M,Hardin BJ, Shulman HM, Clift RA. Veno-occlusive disease of the liver andmultiorgan failure after bone marrow transplantation: a cohort study of355 patients. Ann Intern Med 1993;118:255-267.28. Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG,Vogelsang GB, Sensenbrenner LL, Santos GW, Saral R. Venoocclusive diseaseof the liver following bone marrow transplantation. Transplantation1987;44:778-783.29. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ formedical statistics. Bone Marrow Transplant 2013;48:452-458.30. Kumar S, Tzimas MN, Griswold DE, Young PR. Expression of ST2, aninterleukin-1 receptor homologue, is induced by proinflammatory stimuli.Biochem Biophys Res Commun 1997;235:474-478.31. Rossler U, Thomassen E, Hultner L, Baier S, Danescu J, Werenskiold AK.Secreted and membrane-bound isoforms of T1, an orphan receptorrelated to IL-1-binding proteins, are differently expressed in vivo. Dev Biol1995;168:86-97.32. Schots R, Kaufman L, Van Riet I, Ben Othman T, De Waele M, Van Camp B,Demanet C. Proinflammatory cytokines and their role in the development ofmajor transplant-related complications in the early phase after allogeneicbone marrow transplantation. Leukemia 2003;17:1150-1156.28
Turk J Hematol 2020;37:20-29Matsumura A, et al: ST2 for Transplant-related ComplicationsFigure S1. ROC curves of sST2, CRP, and ferritin for predicting the development of acute GVHD. A) ROC curves for sST2 with area underthe curve (AUC) before conditioning and on days 0, 14, 21, and 28 after transplantation. B) ROC curves for CRP and ferritin with AUCon day 14.sST2: Suppression of tumorigenicity 2, CRP: C-reactive protein, GVHD: Graft-versus-host disease, AUC: Area under the curve, ROC: Receiver operatingcharacteristics.29
Page 1: Volume 37 Issue 1March 2020E-ISSN:
Page 4 and 5: Contact InformationEditorial Corres
Page 6 and 7: TURKISH JOURNAL OF HEMATOLOGYINSTRU
Page 8 and 9: published research articles on the
Page 10 and 11: e-mail address. The system will sen
Page 12 and 13: 59 Children with Iron Deficiency An
Page 14 and 15: Aladağ E, et al: Acute Graft-Versu
Page 16 and 17: Aladağ E, et al: Acute Graft-Versu
Page 18 and 19: Koca D, et al: Therapeutic Potentia
Page 26 and 27: Li SJ, et al: The Efficacy and Safe
Page 32 and 33: RESEARCH ARTICLEDOI: 10.4274/tjh.ga
Page 34 and 35: Matsumura A, et al: ST2 for Transpl
Page 44 and 45: Niazkar HR, et al: First-time Blood
Page 46 and 47: Niazkar HR, et al: First-time Blood
Page 50 and 51: Gonzalez-Mancera MS, et al: Double-
Page 52 and 53: Gonzalez-Mancera MS, et al: Double-
Page 54 and 55: PERSPECTIVES IN HEMATOLOGYDOI: 10.4
Page 56 and 57: Haznedaroğlu İC, et al: Tyrosine
Page 58 and 59: Haznedaroğlu İC, et al: Tyrosine
Page 60 and 61: BRIEF REPORTDOI: 10.4274/tjh.galeno
Page 62 and 63: Demiröz AS, et al: Blastic Plasmac
Page 64 and 65: Demiröz AS, et al: Blastic Plasmac
Page 66 and 67: Pantelic M, et al: Kasabach-Merritt
Page 68 and 69: Ardıçoğlu Akışın Y and Akar N
Page 70 and 71: LETTERS TO THE EDITOR Turk J Hemato
Page 72 and 73: LETTERS TO THE EDITORTurk J Hematol
Page 88: LETTERS TO THE EDITORTurk J Hematol

full

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?